Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
BRIEF-Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis Sept 28 (Reuters) - ADICET Bio, Inc. ACET.O:
ADICET BIO ANNOUNCES POSITIVE SAFETY AND EFFICACY DATA FROM PRULA-CEL (FORMERLY ADI-001) STUDY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH OR WITHOUT LUPUS NEPHRITIS
ADICET BIO, - PRULA-CEL SHOWN TO BE WELL TOLERATED WITH NO CRS ABOVE GRADE 2 AND NO IEC-HS OR ICANS
ADICET BIO, - PLANS TO INITIATE PIVOTAL LUPUS NEPHRITIS TRIAL START-UP ACTIVITIES IN Q4 2026
ADICET BIO, - ALL PATIENTS DISCONTINUED IMMUNOSUPPRESSANTS
ADICET BIO, - AT 12 MONTHS, 54% ACHIEVED DORIS REMISSION AND 50% ACHIEVED COMPLETE RENAL RESPONSE
ADICET BIO, - ANTICIPATED CLINICAL DATA UPDATE IN LUPUS NEPHRITIS/SYSTEMIC LUPUS ERYTHEMATOSUS IN MID 2027
Source text: ID:nBw6Z6cRDa
Further company coverage: ACET.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary